(Q38118343)

29 August 2017

title

Psoriatic arthritis: current therapy and future directions (English)

1 reference

29 August 2017

1 reference

DoQuyen Huynh

1

1 reference

29 August 2017

Arthur Kavanaugh

series ordinal

2

1 reference

29 August 2017

language of work or name

English

0 references

publication date

2 July 2013

1 reference

Expert Opinion on Pharmacotherapy

29 August 2017

published in

1 reference

29 August 2017

volume

14

1 reference

29 August 2017

issue

13

1 reference

29 August 2017

page(s)

1755-1764

1 reference

Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.810208

Distinct synovial immunopathologic characteristics of juvenile-onset spondylarthritis and other forms of juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.810208

IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8- entheseal resident T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.810208

Immunomodulation in psoriatic arthritis: focus on cellular and molecular pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.810208

Update on biomarkers in psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.810208

European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.810208

Treatment recommendations for psoriatic arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.810208

The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6-month trial with methotrexate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.810208

Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.810208

Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.810208

A randomized placebo-controlled trial of methotrexate in psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.810208

Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.810208

Leflunomide in psoriatic arthritis: results from a large European prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.810208

Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.810208

A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.810208

Treatment of psoriatic arthritis with biological agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.810208

Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.810208

Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.810208

Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.810208

Ectopic lymphoid neogenesis in psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.810208

Rituximab treatment for spondyloarthritis. A nationwide series: data from the AIR registry of the French Society of Rheumatology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.810208

Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.810208

Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.810208

Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.810208

Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.810208

Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.810208

Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.810208

Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.810208

10.1517/14656566.2013.810208

21 January 2018

Identifiers

DOI

1 reference

29 August 2017

1 reference